Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Terril Brothers Inc.

Terril Brothers Inc. lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 38.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 151,263 shares of the biopharmaceutical company’s stock after selling 94,545 shares during the quarter. Bristol-Myers Squibb makes up about 2.3% of Terril Brothers Inc.’s portfolio, making the stock its 12th biggest holding. Terril Brothers Inc.’s holdings in Bristol-Myers Squibb were worth $6,282,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Gryphon Financial Partners LLC boosted its stake in Bristol-Myers Squibb by 23.5% during the 4th quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 995 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its stake in Bristol-Myers Squibb by 19.8% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 62,786 shares of the biopharmaceutical company’s stock worth $3,222,000 after purchasing an additional 10,373 shares during the last quarter. Thoroughbred Financial Services LLC boosted its stake in Bristol-Myers Squibb by 4.8% during the 4th quarter. Thoroughbred Financial Services LLC now owns 23,095 shares of the biopharmaceutical company’s stock worth $1,185,000 after purchasing an additional 1,065 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Bristol-Myers Squibb by 12.0% during the 4th quarter. Clearbridge Investments LLC now owns 125,980 shares of the biopharmaceutical company’s stock worth $6,464,000 after acquiring an additional 13,534 shares during the period. Finally, Sachetta LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $57,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on BMY shares. TD Cowen lifted their price target on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a report on Monday. Barclays lifted their price target on Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a report on Thursday, August 22nd. Deutsche Bank Aktiengesellschaft reduced their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group boosted their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $55.00.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $50.00 on Tuesday. The company has a market cap of $101.36 billion, a P/E ratio of -16.13, a P/E/G ratio of 12.59 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The stock has a 50-day moving average of $46.99 and a two-hundred day moving average of $46.47. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $59.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same period in the previous year, the company posted $1.75 earnings per share. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.80%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.